A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy
Authors
Keywords
-
Journal
FEBS Journal
Volume 285, Issue 7, Pages 1203-1211
Publisher
Wiley
Online
2017-11-30
DOI
10.1111/febs.14347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis
- (2017) Yingying Chen et al. HUMAN PATHOLOGY
- DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain
- (2017) Samira Abu Jhaisha et al. Scientific Reports
- Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
- (2016) Zhen Li et al. CANCER LETTERS
- To wake up cancer stem cells, or to let them sleep, that is the question
- (2016) Shoichiro Takeishi et al. CANCER SCIENCE
- A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy
- (2016) James MacDonald et al. MOLECULAR CANCER RESEARCH
- DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway
- (2016) Rajeev Singh et al. Oncotarget
- DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance
- (2016) Wolfgang Gruber et al. Oncotarget
- DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
- (2016) Arnaud Duchon et al. Frontiers in Behavioral Neuroscience
- The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2
- (2016) Florian Glenewinkel et al. Scientific Reports
- Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome
- (2015) Anne L. Ashford et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- DYRK protein kinases
- (2015) Ulf Soppa et al. CURRENT BIOLOGY
- DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3
- (2015) Benjamin J. Thompson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis
- (2015) Jason G. Kettle et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase
- (2015) L.-N. Song et al. MOLECULAR CANCER RESEARCH
- Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1
- (2015) Philipp Schneider et al. Nature Communications
- Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer
- (2015) Jangsoon Lee et al. Journal of Cancer
- Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
- (2014) Xiaobing Deng et al. CARCINOGENESIS
- The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation
- (2014) Ulf Soppa et al. CELL CYCLE
- A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B
- (2014) Ali R. Keramati et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors
- (2014) Christian Schmitt et al. PLoS One
- A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288
- (2013) Anne L. Ashford et al. BIOCHEMICAL JOURNAL
- Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells
- (2013) Jingchun Gao et al. Cancer Cell International
- The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis
- (2013) S. Boichuk et al. CANCER RESEARCH
- Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms
- (2013) Lin Tang et al. CELL CYCLE
- Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle
- (2013) Jia-Yun Chen et al. MOLECULAR CELL
- Modulation of oxidative stress as an anticancer strategy
- (2013) Chiara Gorrini et al. NATURE REVIEWS DRUG DISCOVERY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control
- (2012) Walter Becker CELL CYCLE
- Staying alive
- (2012) James R. Valcourt et al. CELL CYCLE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice
- (2012) T. Masuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
- (2011) L. Litovchick et al. GENES & DEVELOPMENT
- Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
- (2011) D. Z. Ewton et al. MOLECULAR CANCER THERAPEUTICS
- Dyrk1a activates antioxidant NQO1 expression through an ERK1/2–Nrf2 dependent mechanism
- (2011) Christophe Noll et al. MOLECULAR GENETICS AND METABOLISM
- Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
- (2010) Jingchun Gao et al. CANCER BIOLOGY & THERAPY
- DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles
- (2010) Sergi Aranda et al. FASEB JOURNAL
- Activation, regulation, and inhibition of DYRK1A
- (2010) Walter Becker et al. FEBS Journal
- Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2
- (2010) Jing Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Dyrk1A Overexpression Inhibits Proliferation and Induces Premature Neuronal Differentiation of Neural Progenitor Cells
- (2010) O. Yabut et al. JOURNAL OF NEUROSCIENCE
- DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS
- (2010) Matthias Lauth et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer
- (2010) Eileen Friedman Cancers
- Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species
- (2009) X. Deng et al. CANCER RESEARCH
- The kinase Mirk is a potential therapeutic target in osteosarcoma
- (2009) C. Yang et al. CARCINOGENESIS
- Mirk Regulates the Exit of Colon Cancer Cells from Quiescence
- (2009) Kideok Jin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
- (2009) Dunyaporn Trachootham et al. NATURE REVIEWS DRUG DISCOVERY
- FOXOs, cancer and regulation of apoptosis
- (2008) Z Fu et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started